ロード中...
Toward a Single-Dose Cure for Buruli Ulcer
A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a negle...
保存先:
| 出版年: | Antimicrob Agents Chemother |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Microbiology
2020
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7449209/ https://ncbi.nlm.nih.gov/pubmed/32631818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00727-20 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|